Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook






Unwrapping the mystery behind BRCA1

12 September 2011

By Sarah Guy

Appeared in BioNews 624

Researchers based in the USA and the Netherlands report study findings that may explain why women with mutations in the BRCA1 gene are more susceptible to breast and ovarian cancer.

Joint lead author Dr Gerald Pao, from the Salk Institute for Biological Studies, La Jolla, California, and colleagues say that the lack of, or mutation in, BRCA1 leads to activation of normally silent DNA, which causes cells not to repair properly, divide haphazardly and can lead to chromosomal abnormalities, all of which can cause cancer.

Blood tests that can detect the RNA of this normally silent, so-called 'junk DNA' could help doctors detect breast cancer, particularly among younger women whose firm, healthy breast tissue can disguise tumours on ultrasound scans, explained Dr Pao.

Co-author on the study, Professor Inder Verma, said that: 'The issue of what BRCA1 does has been marred in controversy because people kept finding it everywhere, and there was no consistent picture of what it was doing'.

He added: 'We hope this study now provides a new cohesive direction for BRCA1 research so that we can answer the fundamental questions about how this gene promotes cancer and how we might be able to improve early diagnosis and, possibly, treat BRCA1-induced cancer more effectively'.

Over 230,000 women in the USA are diagnosed with breast cancer annually, and almost 10 percent of them will have mutations in either BRCA1 or BRCA2.

The team made their discovery during a study involving mice that had their copy of the BRCA1 gene 'knocked-out'. The DNA in the cells of these mice was not 'packaged' correctly. 'Every chromosome is packaged into chromatin, and within this chromatin there is heterochromatin, which is even further condensed in order to ensure the genes within are really silent', said Dr Pao.

While the findings indicate what a loss or mutation of BRCA1 could lead to, they do not show conclusively how the loose packaging of such DNA actually causes cell mutation and tumour development.

 

SOURCES & REFERENCES
Nature | 07 September 2011
 
Nature News | 07 September 2011
 
Cancer Network | 07 September 2011
 
Sign on San Diego | 08 September 2011
 
Health Canal | 08 September 2011
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

27 February 2012 - by Luciana Strait 
A new genetic mutation linked to a greater risk of developing breast cancer has been shown to interact with the well-known breast cancer-causing gene BRCA1... [Read More]
19 December 2011 - by Dr Rebecca Robey 
Women who inherit breast cancer risk genes from their father may be diagnosed with, or even develop, the disease several years earlier than those who inherit the same genes from their mother. This may have implications for screening and treatment strategies for those at risk of hereditary breast cancer... [Read More]

15 August 2011 - by Dr Maria Teresa Esposito 
Scientists have discovered a rare genetic fault that raises a woman's risk of developing ovarian cancer six-fold. It has been hailed as the most important discovery in the field in the last ten years, and offers hope for new treatments... [Read More]
24 January 2011 - by Professor Sandy Raeburn 
In June 2010, Teachers.TV issued a series of five videos on 'Genetics and Medicine' (1), covering important elements of genetics aimed at school students between the age of 14 and 16 (2).... [Read More]
14 June 2010 - by MacKenna Roberts 
The Australian Federal Court in Sydney is considering groundbreaking legal action of whether private companies can obtain patents on human genes.... [Read More]
17 May 2010 - by Tamara Hirsch 
Five new genetic variants have been discovered which, in combination, raise the risk of developing breast cancer by 16 per cent, according to a new study in Nature Genetics... [Read More]
07 December 2009 - by Antony Blackburn-Starza 
As our understanding of genetics and associated disorders has developed, many genetic tests performing functions - from predicting certain genetic predispositions and identifying rare monogenetic disorders, to ancestry and other 'novelty' tests - have been introduced to the healthcare market. Many geneticists are concerned about the regulation of these tests, which are performed by the NHS, the private sector, or distributed directly to consumers. Experts are calling for more transparent eval... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust

Advertise your products and services HERE - click for further details

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation

Good Fundraising Code

Find out more about the Progress Educational Trust by downloading our brochure HERE